Atezolizumab plus bevacizumab in patients with child–Pugh B advanced hepatocellular carcinoma

BACKGROUND: Atezolizumab plus bevacizumab (Ate/Bev) demonstrated promising efficacy and safety in patients with advanced hepatocellular carcinoma (HCC) in the phase III IMbrave150 trial. However, patients with Child–Pugh B HCC were excluded in the abovementioned prospective trial. Therefore, we aime...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheon, Jaekyung, Kim, Hyeyeong, Kim, Han Sang, Kim, Chang Gon, Kim, Ilhwan, Kang, Beodeul, Kim, Chan, Jung, Sanghoon, Ha, Yeonjung, Chon, Hong Jae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495918/
https://www.ncbi.nlm.nih.gov/pubmed/37705533
http://dx.doi.org/10.1177/17588359221148541

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495918/
https://www.ncbi.nlm.nih.gov/pubmed/37705533
http://dx.doi.org/10.1177/17588359221148541

Ejemplares similares